These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29620924)

  • 1. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research.
    Strawn JR; Croarkin PE
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):363. PubMed ID: 29620924
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363).
    Weihs KL; Wajsbrot DB; Chiles D; Ramaker S; Chappell P
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):245-246. PubMed ID: 30874454
    [No Abstract]   [Full Text] [Related]  

  • 3. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
    Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
    Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P
    Braz J Med Biol Res; 2016 May; 49(6):. PubMed ID: 27240293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
    Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.
    Mosca D; Zhang M; Prieto R; Boucher M
    J Clin Psychopharmacol; 2017 Apr; 37(2):182-192. PubMed ID: 28146000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.
    Findling RL; Groark J; Tourian KA; Ramaker SA; Chiles D; Yang L; Nichols AI
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):909-921. PubMed ID: 27428303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
    Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
    Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
    Atkinson S; Thurman L; Ramaker S; Buckley G; Jones SR; England R; Wajsbrot D
    CNS Spectr; 2019 Oct; 24(5):496-506. PubMed ID: 30419989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
    Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M
    Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
    Soares CN; Wajsbrot DB; Boucher M
    CNS Spectr; 2020 Jun; 25(3):363-371. PubMed ID: 31060632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
    Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M
    Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
    Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
    J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacological treatment of major depressive disorder in children and adolescents.
    Varley CK
    JAMA; 2003 Aug; 290(8):1091-3. PubMed ID: 12941683
    [No Abstract]   [Full Text] [Related]  

  • 17. Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder.
    Hellerstein DJ; Stewart JW; Chen Y; Arunagiri V; Peterson BS; McGrath PJ
    J Affect Disord; 2019 Feb; 245():403-411. PubMed ID: 30423468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.
    Feiger AD; Tourian KA; Rosas GR; Padmanabhan SK
    CNS Spectr; 2009 Jan; 14(1):41-50. PubMed ID: 19169187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.